Home > Oncology > ESMO 2020 > Genitourinary Cancers > First-line immune-combination therapies in mUC

First-line immune-combination therapies in mUC


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Trial
Phase 3, KEYNOTE-361
Two trials, KEYNOTE-361 and DANUBE, explored the efficacy of first-line treatment of patients with metastatic urothelial cancer (mUC) with an immune checkpoint inhibitor combined with either chemotherapy or a second immune checkpoint inhibitor. None of the studies met its endpoint. The current first-line treatment for mUC is platinum-based chemotherapy or best supportive care in case of platinum-ineligibility. Recently, monotherapy with pembrolizumab and atezolizumab were approved for patients with PD-L1 positive disease [1,2]. In the open-label, phase 3 KEYNOTE-361 study, 1,010 patients with unresectable or mUC and who had no prior systemic therapy for advanced disease were 1:1:1 randomised to receive pembrolizumab (200 mg every 3 weeks up to 35 cycles), pembrolizumab plus chemotherapy (gemcitabine plus cisplatin or carboplatin) or chemotherapy [3]. Median progression-free survival (PFS) was 8.3 months in the pembrolizumab plus chemotherapy arm ve...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on